医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Promega Corporation Brings High-Performance DNA Analysis to the Benchtop with New Spectrum Compact CE Instrument

2017年02月14日 PM11:00
このエントリーをはてなブックマークに追加


 

MADISON, Wis.

Soon scientists will be able to perform efficient DNA analysis right at their bench. Promega Corporation has announced the development of a benchtop capillary electrophoresis (CE) instrument in collaboration with Hitachi High-Technologies Corporation. The Spectrum Compact CE System meets small batch and single sample needs in DNA analysis and performs both sequencing and fragment analysis at a moment’s notice.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170214005410/en/

Promega Corporation has announced the development of a benchtop capillary electrophoresis (CE) instr ...

Promega Corporation has announced the development of a benchtop capillary electrophoresis (CE) instrument in collaboration with Hitachi High-Technologies Corporation. The Spectrum Compact CE System meets small batch and single sample needs in DNA analysis and performs both sequencing and fragment analysis at a moment’s notice, allowing scientists to perform efficient DNA analysis right at their bench. (Photo: Business Wire)

The Spectrum Compact CE System allows laboratories of all sizes the freedom to carry out single nucleotide polymorphism, PCR sizing and microsatellite analysis, de novo sequencing, NGS validation, and mutation detection. This benchtop CE instrument runs up to 32 samples at once and features 4-capillary, 6-dye detection along with an integrated touch-screen for instrument operation. Plug-and-play prefilled reagent cartridges with a guided software user interface brings capillary electrophoresis capabilities to the hands of any scientist in the laboratory regardless of skill level or expertise.

“This opens new possibilities to scientists seeking high quality DNA detection on a smaller scale,” says Doug Storts, Head of Research – Nucleic Acid Technologies at Promega. “This system supports the unique workflows of the lab versus the lab needing to batch samples as a work around and cost savings measure when using a high throughput instrument or service. When we ask for early input from labs worldwide, the consistent response we get from scientists is ‘thank you’.”

The first prototype will be on display at the Advances in Genome Biology and Technology Meeting February 13-16, 2017. It will also be featured at the American Academy of Forensic Sciences Annual Meeting February 13-18, 2017. It is anticipated to be commercially available in the second half of 2017.

The collaboration between Promega and Hitachi High-Technologies leverages the two companies’ respective strengths as the industry’s leading manufacturer of reagents and STR kits and the world’s chief developer of capillary electrophoresis, allowing them to offer a high-performing, high-value, compact capillary electrophoresis instrument.

Promega will also release a new Sanger sequencing kit designed for the Spectrum Compact CE System that features increased base-calling accuracy and applies Promega expertise in enzymology, dye manufacturing and master mixes. The Spectrum Compact CE System joins the Promega Spectrum CE System to support laboratories worldwide and is for research use only.

To learn more about the Spectrum Compact CE System, visit www.promega.com/NewSpectrumCompact.

About Hitachi High-Technologies Corporation

Hitachi High-Technologies Corporation, headquartered in Tokyo, Japan, is engaged in activities in a broad range of fields, including Science & Medical Systems, Electronic Device Systems, Industrial Systems, and Advanced Industrial Products. The company’s consolidated sales for FY2015 were approx. JPY629 billion [USD6 billion]. For further information, visit http://www.hitachi-hitec.com/global/.

About Promega Corporation

Promega Corporation has provided products for DNA-based human identification for more than 25 years. Promega is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 3,500 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170214005410/en/

CONTACT

Promega Corporation
Penny Patterson
Sr. Director,
Communications
Phone: (608) 274-4330
E-mail: penny.patterson@promega.com

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続